BioKangtai(SZ:300601) Sou Hu Cai Jing·2025-11-25 14:01Core Viewpoint - Kangtai Biological announced a stock pledge by its controlling shareholder, Du Weimin, involving 3,050,000 shares, which represents 1.07% of his holdings and 0.27% of the company's total shares. The pledge is for industrial investment and does not pose risks to the company's control or operations [2]. Company Overview - Kangtai Biological was established on September 8, 1992, with a registered capital of 11,169.12463 million RMB. The company specializes in the research, production, and sales of human vaccines [2]. - The current chairman is Du Weimin, and the company employs 1,913 people [2]. Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the first three quarters of 2025 were 3.157 billion RMB, 3.477 billion RMB, 2.652 billion RMB, and 2.063 billion RMB, reflecting year-on-year changes of -13.55%, 10.14%, -23.75%, and 2.24% respectively [3]. - The net profit attributable to the parent company for the same periods were -133 million RMB, 861 million RMB, 202 million RMB, and 49.157 million RMB, with year-on-year growth rates of -110.50%, 749.02%, -76.59%, and -86.00% respectively [3]. - The company's asset-liability ratios for the same periods were 34.82%, 36.75%, 33.66%, and 32.01% [3]. Risk Assessment - The company has a total of 142 risk items listed on Tianyancha, with 91,480 surrounding risks, 174 historical risks, and 94 warning risks [3].